as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹641.95
Change
-11.05 (-1.69%)
Open
₹653.0
Prev. Close
₹653.0
Day High
₹656.1
Day Low
₹640.0
Volume Analysis
Traded
60,125
Delivered
28,947
Delivery %
48.14%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (21.0%)
Weaknesses (2)
- •Low return on equity (8.83%)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year revenue growth (31.7%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹668.14 | ₹662.12 | ₹652.04 | ₹646.02 | ₹635.94 | ₹629.92 | ₹619.84 |
| Fibonacci | ₹662.12 | ₹655.97 | ₹652.17 | ₹646.02 | ₹639.87 | ₹636.07 | ₹629.92 |
| Camarilla | ₹646.38 | ₹644.9 | ₹643.43 | ₹646.02 | ₹640.47 | ₹639.0 | ₹637.52 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+40.84%
1 Week
+3.1%
1 Month
+5.43%
3 Months
-7.51%
6 Months
+5.67%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹142.61
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
9.64%
Net margin 11.53% × asset turnover 0.61x × equity multiplier 1.37x
Company Overview
Sector
Healthcare
Market Cap
₹6,500 Cr
P/E (TTM)
50.8
ROE
8.83%
Book Value
₹118.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.
TopFund Analysis
Nephrocare Health Serv L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Financial Strength (100/100), while Valuation (16/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (21.0%); low return on equity (8.83%); promoter holding is falling. Strong 3-year revenue growth (31.7%).
TopFund Score — Fundamentals Quality
64/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company has delivered good profit growth of 162% CAGR over last 5 years
- −Stock is trading at 5.45 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Promoter holding has decreased over last quarter: -5.53%
- −Company has a low return on equity of 10.2% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
NRC approved 38,236 ESOPs under ESOP 2026 at ₹513.60 each on November 17, 2026.
The Company has approved allotment of 3,42,130 equity shares of Rs. 2/- each, pursuant to the exercise of stock ....
Transcripts for the Investors Earnings call held on November 4, 2026.
The Company has scheduled an investor conference call as per the disclosure annexed herewith.
Uploaded audio recording of Q2FY27 investor conference call held on November 4, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 197 | 219 | 228 | 246 | 260 | 266 | 282 | 303 |
| Expenses + | 153 | 168 | 180 | 182 | 199 | 215 | 221 | 240 |
| Operating Profit | 44 | 51 | 48 | 64 | 61 | 51 | 60 | 63 |
| OPM % | 22.0% | 23.0% | 21.0% | 26.0% | 23.0% | 19.0% | 21.0% | 21.0% |
| Other Income + | 5 | 4 | 7 | 4 | 3 | 12 | 7 | 8 |
| Interest | 5 | 6 | 6 | 45 | 6 | 3 | 2 | 3 |
| Depreciation | 18 | 19 | 20 | 23 | 22 | 26 | 25 | 28 |
| Profit before tax | 26 | 30 | 29 | -1 | 36 | 33 | 41 | 40 |
| Tax % | 24.0% | 17.0% | 17.0% | 1,427.0% | 11.0% | 9.0% | 22.0% | 17.0% |
| Net Profit + | 20 | 25 | 24 | -9 | 32 | 30 | 32 | 34 |
| EPS in Rs | 2 | 3 | 3 | -1 | 3 | 3 | 3 | 3 |
| Raw PDF | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | 32 | 21 | 24 | 23 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales + | 286 | 318 | 437 | 566 | 756 | 999 | 1,110 |
| Expenses + | 248 | 302 | 389 | 465 | 589 | 774 | 875 |
| Operating Profit | 37 | 16 | 49 | 101 | 167 | 225 | 235 |
| OPM % | 13.0% | 5.0% | 11.0% | 18.0% | 22.0% | 23.0% | 21.0% |
| Other Income + | 5 | 10 | 6 | 8 | 14 | 23 | 30 |
| Interest | 7 | 10 | 16 | 20 | 21 | 60 | 14 |
| Depreciation | 34 | 42 | 47 | 56 | 72 | 91 | 100 |
| Profit before tax | 1 | -27 | -9 | 33 | 87 | 97 | 151 |
| Tax % | 31.0% | -21.0% | 37.0% | -6.0% | 23.0% | 21.0% | — |
| Net Profit + | 1 | -21 | -12 | 35 | 67 | 77 | 128 |
| EPS in Rs | 0 | -2 | -1 | 4 | 7 | 8 | 13 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | — | 11 | 38 | 29 | 34 | 32 | 25 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Reserves | 245 | 391 | 384 | 409 | 579 | 1,096 | 1,169 |
| Borrowings + | 140 | 119 | 200 | 271 | 261 | 80 | 149 |
| Other Liabilities + | 42 | 59 | 81 | 124 | 153 | 271 | 295 |
| Total Liabilities | 428 | 571 | 666 | 806 | 994 | 1,467 | 1,633 |
| Fixed Assets + | 192 | 205 | 239 | 356 | 396 | 517 | 634 |
| CWIP | 2 | 43 | 34 | 1 | 6 | 6 | 7 |
| Investments | 0 | 0 | 0 | 0 | 51 | 178 | 214 |
| Other Assets + | 234 | 322 | 393 | 449 | 542 | 767 | 778 |
| Total Assets | 428 | 571 | 666 | 806 | 994 | 1,467 | 1,633 |
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 20 | 20 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 32 | 14 | 11 | 72 | 135 | 233 |
| Cash from Investing Activity + | -62 | -130 | -76 | -52 | -125 | -392 |
| Cash from Financing Activity + | 36 | 121 | 60 | 27 | 54 | 157 |
| Net Cash Flow | 5 | 6 | -4 | 47 | 65 | -2 |
| Free Cash Flow | -29 | -64 | -62 | -8 | 35 | 113 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 49 | 119 | 14 | 80 | 82 | 116 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|
| Public | 18.74% | 17.56% | 18.3% | 21.85% |
| Promoters | 63.85% | 63.85% | 63.85% | 58.32% |
| FII | 9.3% | 9.94% | 8.78% | 11.73% |
| DII | 8.1% | 8.64% | 9.05% | 8.11% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Nephrocare Health Serv L (this stock) | 6,500 | 50.8 | 5.46 | 8.83% |
| Sun Pharma Adv.res.co.ltd | 6,680 | 4.05 | 4.64 | 279.0% |
| Fdc Limited | 6,177 | 18.8 | 2.31 | 11.5% |
| Innova Captab Limited | 5,938 | 35.6 | 5.09 | 13.7% |
| Bliss Gvs Pharma Ltd | 7,075 | 43.5 | 5.5 | 11.8% |
| Kovai Medical Center & Ho | 7,108 | 123.0 | 24.58 | 22.2% |
| Sanofi India Limited | 7,375 | 16.7 | 8.56 | 47.1% |
Which Mutual Funds Hold Nephrocare Health Serv L?
Frequently Asked Questions about Nephrocare Health Serv L
Nephrocare Health Serv L (NEPHROPLUS) closed at ₹641.95 on NSE on 19 November 2026, down 11.05 (1.69%) from the previous close.
Nephrocare Health Serv L trades on the NSE (National Stock Exchange of India) under the symbol NEPHROPLUS.
Nephrocare Health Serv L has a trailing twelve-month P/E (price-to-earnings) ratio of 50.8.
Nephrocare Health Serv L has a dividend yield of 0.0%.
Nephrocare Health Serv L's 52-week high is ₹782.0 and its 52-week low is ₹445.0.
Nephrocare Health Serv L has a market capitalisation of ₹6,500 crore.
Nephrocare Health Serv L has a TopFund Quality Score of 64/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Nephrocare Health Serv L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.